<i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine
Emerging influenza viruses pose an extreme global risk to human health, resulting in an urgent need for effective vaccination against influenza infection. Adjuvants are vital components that can improve vaccine efficacy, yet only a few adjuvants have been licensed in human vaccines. Here, we investi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/2/306 |
| _version_ | 1797565217846067200 |
|---|---|
| author | Quyen Thi Nguyen Eunjin Kim Jihyun Yang Chankyu Lee Da Hui Ha Choon Geun Lee Ye Ram Lee Haryoung Poo |
| author_facet | Quyen Thi Nguyen Eunjin Kim Jihyun Yang Chankyu Lee Da Hui Ha Choon Geun Lee Ye Ram Lee Haryoung Poo |
| author_sort | Quyen Thi Nguyen |
| collection | DOAJ |
| description | Emerging influenza viruses pose an extreme global risk to human health, resulting in an urgent need for effective vaccination against influenza infection. Adjuvants are vital components that can improve vaccine efficacy, yet only a few adjuvants have been licensed in human vaccines. Here, we investigate the adjuvant effects of <i>Escherichia coli</i>-produced monophosphoryl lipid A (MPL), named EcML, in enhancing the immunogenicity and efficacy of an influenza vaccine. Similar to MPL, EcML activated dendritic cells and enhanced the antigen processing of cells in vitro. Using ovalbumin (OVA) as a model antigen, EcML increased OVA-specific antibody production, cytotoxic T lymphocyte activity. The safety of EcML was demonstrated as being similar to that of MPL by showing not significant in vitro cell cytotoxicity but transient systemic inflammatory responses within 24 h in OVA immunized mice. Importantly, mice vaccinated with pandemic H1N1 (pH1N1) vaccine antigen, combined with EcML, were fully protected from pH1N1 virus infection by enhanced influenza-specific antibody titers, hemagglutination inhibition titers, and IFN-γ- secreting cells. Taken together, our results strongly suggest that EcML might be a promising vaccine adjuvant for preventing influenza virus infection. |
| first_indexed | 2024-03-10T19:08:58Z |
| format | Article |
| id | doaj.art-38378a5240ff4c63b249773ae3f654fa |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T19:08:58Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-38378a5240ff4c63b249773ae3f654fa2023-11-20T03:57:56ZengMDPI AGVaccines2076-393X2020-06-018230610.3390/vaccines8020306<i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 VaccineQuyen Thi Nguyen0Eunjin Kim1Jihyun Yang2Chankyu Lee3Da Hui Ha4Choon Geun Lee5Ye Ram Lee6Haryoung Poo7Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, KoreaInfectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, KoreaInfectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, KoreaEubiologics. Co., Ltd., V Plant, Gangwon-do 24410, KoreaEubiologics. Co., Ltd., V Plant, Gangwon-do 24410, KoreaEubiologics. Co., Ltd., V Plant, Gangwon-do 24410, KoreaEubiologics. Co., Ltd., V Plant, Gangwon-do 24410, KoreaInfectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, KoreaEmerging influenza viruses pose an extreme global risk to human health, resulting in an urgent need for effective vaccination against influenza infection. Adjuvants are vital components that can improve vaccine efficacy, yet only a few adjuvants have been licensed in human vaccines. Here, we investigate the adjuvant effects of <i>Escherichia coli</i>-produced monophosphoryl lipid A (MPL), named EcML, in enhancing the immunogenicity and efficacy of an influenza vaccine. Similar to MPL, EcML activated dendritic cells and enhanced the antigen processing of cells in vitro. Using ovalbumin (OVA) as a model antigen, EcML increased OVA-specific antibody production, cytotoxic T lymphocyte activity. The safety of EcML was demonstrated as being similar to that of MPL by showing not significant in vitro cell cytotoxicity but transient systemic inflammatory responses within 24 h in OVA immunized mice. Importantly, mice vaccinated with pandemic H1N1 (pH1N1) vaccine antigen, combined with EcML, were fully protected from pH1N1 virus infection by enhanced influenza-specific antibody titers, hemagglutination inhibition titers, and IFN-γ- secreting cells. Taken together, our results strongly suggest that EcML might be a promising vaccine adjuvant for preventing influenza virus infection.https://www.mdpi.com/2076-393X/8/2/306adjuvantvaccine efficacyinfluenza virusmonophosphoryl lipid Aantibody productioncytotoxic T lymphocyte |
| spellingShingle | Quyen Thi Nguyen Eunjin Kim Jihyun Yang Chankyu Lee Da Hui Ha Choon Geun Lee Ye Ram Lee Haryoung Poo <i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine Vaccines adjuvant vaccine efficacy influenza virus monophosphoryl lipid A antibody production cytotoxic T lymphocyte |
| title | <i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine |
| title_full | <i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine |
| title_fullStr | <i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine |
| title_full_unstemmed | <i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine |
| title_short | <i>E. coli</i>-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine |
| title_sort | i e coli i produced monophosphoryl lipid a significantly enhances protective immunity of pandemic h1n1 vaccine |
| topic | adjuvant vaccine efficacy influenza virus monophosphoryl lipid A antibody production cytotoxic T lymphocyte |
| url | https://www.mdpi.com/2076-393X/8/2/306 |
| work_keys_str_mv | AT quyenthinguyen iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT eunjinkim iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT jihyunyang iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT chankyulee iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT dahuiha iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT choongeunlee iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT yeramlee iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine AT haryoungpoo iecoliiproducedmonophosphoryllipidasignificantlyenhancesprotectiveimmunityofpandemich1n1vaccine |